Lenz & Staehelin: Mablink Bioscience to be acquired by Lilly
Mablink Bioscience, a pre-clinical company pioneering the development of next-generation antibody-drug conjugates via its PSARLinkTM proprietary platform, announced an agreement to be acquired by Eli Lilly and Company. The biotechnology company is developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs).
The transaction is subject to approval from the French Ministry of the Economy. The pending acquisition reflects the potential of Mablink’s existing pipeline.
Lenz & Staehelin advises Lilly in this transaction. The team includes partner Tino Gaberthüel (pictured) and associate Xavier Grivel (both M&A, pictured right) and Martin Aebi (counsel, IP/litigation).
